After reaching an important support level, Zoetis (ZTS) could be a good stock pick from a technical perspective. ZTS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.Similar to other SMA ...

From a technical perspective, Zoetis (ZTS) is looking like an interesting pick, as it just reached a key level of support. ZTS recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or re ...

Monty RakusenI published my ‘Hold’ thesis on Zoetis (NYSE:ZTS) in July 2023, highlighting the high quality of Zoetis’ companion business while expressing concerns about its elevated stock price. Since my last publication, the stock price increased by 8.6%, underperforming compared to the S&P 500 (SP500) index return of 15.8%. The company released its Q2 earnings on August 6th before the market opened and raised its full-year guidance. I believe the companion business will experience double-digit growth ...

Zoetis (ZTS) reported $2.36 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 8.3%. EPS of $1.56 for the same period compares to $1.41 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.3 billion, representing a surprise of +2.53%. The company delivered an EPS surprise of +4.70%, with the consensus EPS estimate being $1.49.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

Key TakeawaysZoetis raised its full-year revenue guidance by $50 million at the midpoint.The company topped second-quarter expectations on revenue but fell just short on earnings per share (EPS).Shares surged 6% in intraday trading Tuesday. Zoetis (ZTS) stock surged in intraday trading Tuesday after the company beat second-quarter revenue expectations and raised its full-year guidance. The veterinary drugmaker now expects full-year revenue of $9.1 billion to $9.25 billion, up from its prior forecast of $9.0 ...

On Tuesday, Zoetis Inc ZTS stock is trading higher after the company reported better-than-expected second-quarter financial results and raised its 2024 guidance above estimates.The animal health company reported second-quarter revenue of $2.36 billion, up 8% year-over-year on reported and 11% on an operational basis, beating the consensus of $2.31 billion.“We achieved 12% revenue growth in the U.S. and 10% operational revenue growth internationally, with both our companion animal and livestock portfolios se ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-069 ...

Zoetis Inc. (NYSE:ZTS) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Brandon Vazquez - William Blair Christopher LoBianco - TD Cowen Balaji Prasad - Barclays David Westenberg - Piper Sandler Glen Santangelo - Jefferies Chris Schott - JPMorgan Navann Ty - BNP Paribas Tom DeBourcy - Nephron Research Operat ...

Zoetis, Inc. (ZTS) delivered second-quarter 2024 adjusted earnings (excluding one-time items) of $1.56 per share, which surpassed the Zacks Consensus Estimate of $1.49. In the year-ago quarter, the company delivered adjusted earnings of $1.41 per share.Total revenues grew 8% year over year to $2.36 billion in the reported quarter, which also beat the Zacks Consensus Estimate of $2.30 billion. In the year-ago quarter, the company reported total revenues of $2.18 billion.Shares of Zoetis are up in response to ...

It was a classic beat-and-raise quarter for Zoetis.Shares of Zoetis (ZTS 5.98%), the leading animal pharmaceutical maker, were climbing today after the company reported better-than-expected results in its second-quarter earnings report and raised its guidance for the full year.As a result, the stock was up 6.4% as of 10:34 a.m. ET. Zoetis gets back on trackAfter some weakness earlier this year, Zoetis posted solid results with revenue up 8% to $2.36 billion, ahead of estimates at $2.31 billion. Growth was l ...